LOS ANGELES, CA / ACCESSWIRE / June 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against SunPower Corporation (“SunPower” or the “Company”) (NASDAQ: SPWR) regarding possible violations of federal securities laws from February 17, 2016 through August 9, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired SunPower shares during the Class Period should contact the firm prior to the updated July 21, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may do nothing and be an absent class member as well.

According to the Complaint, throughout the Class Period, SunPower made materially false and misleading statements and/or failed to disclose: that a substantial number of its customers were adopting a longer-term timeline for project completion; that SunPower’s near-term economic returns were deteriorating due to aggressive PPA pricing by new market entrants; that market disruption in the YieldCo environment was affecting the Company’s assumptions related to monetizing deferred profits; that as a result, demand for SunPower’s products was significantly declining; that in response, the Company implemented a manufacturing realignment that would result in significant restructuring charges; that the Company’s fiscal year 2016 guidance was overstated; and that as a result of the above, SunPower’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When this news was announced, SunPower’s stock price dropped materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 467170

IRVINE, CA / ACCESSWIRE / June 29, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Sunrun Inc. (“Sunrun” or the “Company”) (NASDAQ: RUN). Investors, who purchased or otherwise acquired shares from September 16, 2015 to May 2, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by the July 3, 2017 lead plaintiff motion deadline.

If you purchased Sunrun securities during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

The Complaint alleges that throughout the Class Period, Sunrun made false and/or misleading statements and/or failed to disclose that: the Company failed to adequately reveal how many customers canceled contracts after signing up for its home-solar energy system; that discovery of this conduct would subject the Company to heightened regulatory scrutiny and potential civil sanctions; and that as a result of the above, Sunrun’s public statements were materially false and misleading at all relevant times. On May 3, 2017, The Wall Street Journal reported that Sunrun was the subject of a U.S. Securities and Exchange Commission (“SEC”) probe and according to a person familiar with the investigation, “[t]he SEC recently issued a subpoena to Sunrun and interviewed current and former employees about the adequacy of its disclosures on account cancellations.” Following this news, Sunrun’s stock price fell materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 467171

LOS ANGELES, CA / ACCESSWIRE / June 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Sky Solar Holdings, Ltd. (“Sky Solar” or the “Company”) (NASDSAQ: SKYS) regarding possible violations of federal securities laws. Investors who purchased or otherwise acquired Sky Solar shares (1) pursuant and/or traceable to the Company’s initial public offering (“IPO”) on or about November 18, 2014; and/or (2) on the open market between November 14, 2014 through June 12, 2017 inclusive (the “Class Period”), should contact the firm prior to the August 15,
2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Sky Solar made false and/or misleading statements, and/or failed to disclose that: the Company’s Code of Business Conduct and Ethics and its enforcement by the Board of Directors were inadequate to detect and/or deter misconduct by its officers and directors; that Sky Solar’s founder, Weili Su, was involved in undisclosed misconduct during his tenure; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was released, shares of Sky Solar fell in value, which harmed investors according to the Complaint.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 467168

LOS ANGELES, CA / ACCESSWIRE / June 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ: NTRP) regarding possible violations of federal securities laws from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Neurotrope shares during the Class Period, should contact the firm prior to the July 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information, regarding the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. When this news reached the public, the Company’s share price fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator located in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 467169

LOS ANGELES, CA / ACCESSWIRE / June 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against PCM, Inc. (“PCM” or the “Company”) (NASDAQ: PCMI) for possible violations of federal securities laws from June 17, 2015 through May 2, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired PCM shares during the Class Period, should contact the firm before the July 3, 2017, the lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, PCM violated federal securities laws. In April 2015, PCM acquired En Pointe Technologies, Inc. and publicly filed its supposed financial statements. On May 2, 2017, Seeking Alpha reported that PCM alleged that En Pointe’s net income was overstated due to several accounting issues and thus its public statements were materially false and misleading at all relevant times. When this information was announced, PCM’s stock priced fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 467167

DALLAS, TX / ACCESSWIRE / June 29, 2017 / Stonegate Capital Partners updates research coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH).

COMPANY DESCRIPTION

Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize™. This technology safely distributes nucleic acid based drugs systemically throughout the body via intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001) is in Phase 2 clinical studies for the treatment of acute and chronic myeloid leukemia (AML and CML), and preclinical studies for solid tumors. The Company’s second DNAbilize™ drug candidate, Liposomal Bcl2 (BP1002), for the treatment of lymphoma, leukemia, colon, prostate and breast cancers, has completed preclinical studies for non-Hodgkin’s lymphoma. Bio-Path is planning a broad Phase 1 clinical trial in lymphoma in 2017. Bio-Path is headquartered in Bellaire, Texas, and currently employs 12 full-time.

SUMMARY

Despite ongoing advancements in the development of nucleic acid drugs, pharmaceutical developers are still facing the challenge of delivering therapeutics to targeted cells without causing severe side effects in the patient. In clinical studies, Bio-Path’s therapeutic platform has delivered a strong, effective therapeutic payload, with no evidence of toxicity. This novel target-based platform has the potential to transform the therapeutic landscape of cancer treatment and also address other diseases that have well-defined targets.

Bio-Path’s pipeline continues to expand with new cancer indications. Importantly, once its DNAbilize™ platform is proven successful for cancer, the core technology can easily be expanded to address new therapeutic areas, including autoimmune diseases.
In contrast to other lipid delivery technologies that have dose-limiting toxicities, DNAbilize™, Bio-Path’s next generation oligonucleotide-based technology, enables the delivery of high doses of therapeutics to target cells, while demonstrating no evidence of toxicity. This lack of toxicity enables the development of therapies to address patients, particularly within the growing elderly population, who are unable to withstand aggressive therapeutic regimens, and therefore, have limited available treatment options.
Bio-Path has completed Phase 1 clinical trials for its lead candidate prexigebersen for AML, CML and other blood cancers, and is in the midst of Phase 2 clinical trial for AML and a Phase 1b/2 clinical trial for CML. Importantly, the Company expects to complete an interim analysis in 2H 2017 of the first 19 patients enrolled in the Phase 2 efficacy trial for AML, with the possibility of switching to a registration trial for accelerated approval.
The clinical targets for BP1002 are lymphoma, and potentially breast cancer, colon cancer, and prostate cancer. This novel, non-toxic, specific Bcl2 inhibitor could be a significant advance in cancer therapeutics, with the potential to treat 40% to 60% of solid tumors, according to Bio-Path estimates.
Bio-Path is collaborating with respected academic and clinical institutions, including M.D. Anderson, Thomas Jefferson University and UT Southwestern, to expand indications inside and outside of cancer, which we view as a validation of Bio-Path’s DNAbilize™ technology. Going forward, we believe the versatility of the DNAbilize™ platform could represent significant drug development and licensing opportunities for Bio-Path.
Recent results include a net loss of $397K for the quarter ended 3/31/17 vs. a net loss of $1.87M for the comparable quarter of prior year. While operating expenses were similar Y-O-Y, the Company recognized a $1.6M gain for the change in fair value of warrants for the most recent quarter. Management states that cash on hand of approximately $7M is sufficient to fund operations for the next 12 months.

With promising clinical data and several programs in the pipeline addressing sizable markets with unmet needs, our valuation analysis for the BP1001 for AML and CML programs alone results in an estimated range of $3.60-$4.45/share, with a mid-point of approximately $3.99. See full report for further details.

The full report can be accessed by clicking the following link:

http://stonegateinc.com/reports/BPTH_Initiation_FINAL_June_2017.pdf

About Stonegate Capital Partners

Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high quality investment opportunities.

SOURCE: Stonegate Capital Partners

ReleaseID: 467130

HOLLYWOOD, CA / ACCESSWIRE / June 29, 2017 / Aftermaster, Inc. (OTCQB: AFTM), an award-winning, industry leading audio company, will be hosting a conference call on Wednesday July 05, 2017 at 4:15 ET to provide investors and interested parties a business update.

Participant Instructions:

Toll Free Dial-In Number: (833) 859-8954
Conference ID: 48239638

ABOUT AFTERMASTER

AfterMaster is a groundbreaking audio technology originally developed for the mastering, re-mastering and processing of audio through AfterMaster HD Audio Labs, Inc. AfterMaster delivers an unparalleled clarity, depth, and fullness to audio recordings, while delivering a significant increase in volume without increased distortion or loss of dynamic range. The technology has been utilized by a number of leading musicians seeking to create a fuller and richer sound quality than otherwise available in digital audio.

Contact Information:

Mark Depew
Senior Vice President
mdepew@aftermaster.com

SOURCE: Aftermaster, Inc.

ReleaseID: 467166

NEW YORK, NY / ACCESSWIRE / June 29, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Synchronoss Technologies, Inc. (“Synchronoss Technologies”) (NASDAQ: SNCR) between October 28, 2015 and April 27, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra-sb/synchronoss-technologies-inc?wire=1 or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Synchronoss would not be able to meet revenue guidance provided to investors; (2) as such, Synchronoss would need to revise its prior guidance; and (3) as a result, defendants’ statements about Synchronoss’ business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you suffered a loss in Synchronoss Technologies you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 467165

NEW YORK, NY / ACCESSWIRE / June 29, 2017 / EXFO Inc. (NASDAQ: EXFO) will be discussing their earnings results in their Q3 Earnings Call to be held June 29, 2017 at 5:00 PM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/24056.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/24056.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 467128